cancer-stem-cells-2019-scientifictracks

Page 22

Cancer Stem Cells 2019

Journal of Medical Oncology andTherapeutics | Volume 4

July 18-19, 2019 | Valencia, Spain

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

CANCER STEM CELLS AND

ONCOLOGY RESEARCH

International Conference on

SALINOMYCIN AS POTENT DRUG TO TARGET CSCS

Divya Sivanesan, Raj Pranap Arun

and

Rama Shanker Verma

Indian Institute of Technology (IIT) - Madras, India

ancer relapse has been an issue in oncology research for more than few decades but author hasn’t reached

at a solution yet. Their study aims at avoiding the recurrence by making conventional therapies more ef-

ficient with adjunct treatment. Cancer stem cells (CSCs) is the root cause for drug/chemo-resistance as these

cells have characteristic properties of stem cells, they are quiescent and are highly invasive. Recent research

article explored various chemical compounds though high-throughput screening which would selectively tar-

get CSCs. Salinomycin is the reported potent drug and we decided to further investigate the same. Colorectal

cell lines DLD1, SW620 and breast cancer cell lines MCF7, MDA-MB-231 cells were used for the study. These

cells were exposed repeatedly to radiation dosage or treated with IC50 concentration of 5-Flurouracil (5-FU)

to generate resistant cell line. Levels of stemness markers like SOX2, KLF4, OCT4 etc. and epithelial-to-mesen-

chymal (EMT) markers like Snail1, Zeb1, E-cadherin, N-cadherin etc., were observed and were compared with

that of untreated cells. There was a significant up regulation in stemness and EMT pathway at transcriptional as

well as at protein level which was evaluated through real-time PCR and western blot, immune cytochemistry

respectively. At as low concentration of salinomycin as 2µM, these markers were down regulated and function-

al assays like colony forming assay and flow cytometry analysis of CD133 and CD44-CSC markers corroborated

the same. Thus, salinomycin could be potent drug to target CSCs avoid secondary tumor formation. Further

understanding of the target mechanism could help us improve the current treatment method.

Divya Sivanesan et al., J Med Oncl Ther 2019, Volume 4

Divya Sivanesan is a PhD scholar working in Stem Cell and Molecular Biology laboratory under the guidance of Prof Rama Shanker

Verma, Biotechnology Department, IIT Madras. She is final year student and has two publications.

BIOGRAPHY